Gaseotransmitters: New frontiers for translational science

Science Translational Medicine

Volumn 2, Issue 59, 2010, Pages

  Szabo, Csaba ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CAPTOPRIL; CARBON MONOXIDE; CARBON MONOXIDE RELEASING MOLECULE; CINACIGUAT; CITRULLINE; CYSTEINE; DICHLOROMETHANE; GYY 4137; HYDROGEN SULFIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INORGANIC COMPOUND; NAPROXCINOD; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRITE; NITROSOTHIOL; NONOATE; OXIDE; PHOSPHODIESTERASE V INHIBITOR; RIOCIGUAT; SILDENAFIL; SODIUM SULFIDE; STEROID; SYDNONIMINE; TADALAFIL; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL PROTECTION; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; DOSE RESPONSE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GAS ANALYSIS; GAS DIFFUSION; GRAFT REJECTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMORRHAGIC SHOCK; HUMAN; HYPERTENSION; HYPOXIA; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SHOCK; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; VASCULAR DISEASE; VASODILATATION; VENTILATOR INDUCED LUNG INJURY; WOUND HEALING; ANIMAL; ARTICLE; DRUG EFFECT; GAS; METABOLISM;

ANIMALS; CARBON MONOXIDE; GASES; HUMANS; HYDROGEN SULFIDE; NITRIC OXIDE; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH;

EID: 78649439251     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000721     Document Type: Review

References (53)

1. "Hydrogen sulfide may kill us, bring us back to life." Wired (3 March 2008); www.wired.com/science/planetearth/news/2008/03/peter-ward-qa? currentPage=all.
2. R. F. Furchgott, The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA 276, 1186-1188 (1996).
3. L. J. Ignarro, G. M. Buga, K. S. Wood, R. E. Byrns, G. Chaudhuri, Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84, 9265-9269 (1987).
4. M. R. Miller, I. L. Megson, Recent developments in nitric oxide donor drugs. Br. J. Pharmacol. 151, 305-321 (2007).
5. Nitric Oxide - Biology and Pathobiology, L. J. Ignarro, Ed. (Academic Press, Maryland Heights, MO, 2009).
6. H. P. Kim, S. W. Ryter, A. M. Choi, CO as a cellular signaling molecule. Annu. Rev. Pharmacol. Toxicol. 46, 411-449 (2006).
7. S. W. Ryter, L. E. Otterbein, Carbon monoxide in biology and medicine. Bioessays 26, 270-280 (2004).
8. C. Szabo, Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 6, 917-935 (2007).
9. H. Kimura, Hydrogen sulfide: From brain to gut. Antioxid. Redox Signal. 12, 1111-1123 (2010).
10. C. S zabo, Medicinal chemistry and therapeutic applications of the gaseotransmitters nitric oxide, carbon monoxide and hydrogen sulfide. In Burger's Medicinal Chemistry (Wiley, Hoboken, NJ, 2010), vol. 5, pp. 235-367.
11. 2S in the body via enzymatic or nonenzymatic mechanisms. Examples of donors are, respectively, organic nitrates, CORMs, and polysulfides.
12. F. Murad, Discovery of some of the biological effects of nitric oxide and its role in cell signaling. Biosci. Rep. 24, 452-474 (2004).
13. J. D. Corbin, S. H. Francis, Cyclic GMP phosphodiesterase-5: Target of sildenafil. J. Biol. Chem. 274, 13729-13732 (1999).
14. P. Dorsey, C. Keel, M. Klavens, W. J. Hellstrom, Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin. Pharmacother. 11, 1109-1122 (2010).
15. K. D. Bloch, F. Ichinose, J. D. Roberts Jr., W. M. Zapol, Inhaled NO as a therapeutic agent. Cardiovasc. Res. 75, 339-348 (2007).
16. J. D. Lang Jr., X. Teng, P. Chumley, J. H. Crawford, T. S. Isbell, B. K. Chacko, Y. Liu, N. Jhala, D. R. Crowe, A. B. Smith, R. C. Cross, L. Frenette, E. E. Kelley, D. W. Wilhite, C. R. Hall, G. P. Page, M. B. Fallon, J. S. Bynon, D. E. Eckhoff, R. P. Patel, Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J. Clin. Invest. 117, 2583-2591 (2007).
17. M. Mathru, R. Huda, D. R. Solanki, S. Hays, J. D. Lang, Inhaled nitric oxide attenuates reperfusion inflammatory responses in humans. Anesthesiology 106, 275-282 (2007).
18. T. Shimazu, H. Ikeuchi, H. Sugimoto, C. W. Goodwin, A. D. Mason Jr., B. A. Pruitt Jr., Half-life of blood carboxyhemoglobin after short-term and long-term exposure to carbon monoxide. J. Trauma 49, 126-131 (2000).
19. E. O. Owens, Endogenous carbon monoxide production in disease. Clin. Biochem. 43, 1183-1188 (2010).
20. E. A. Wintner, T. L. Deckwerth, W. Langston, A. Bengtsson, D. Leviten, P. Hill, M. A. Insko, R. Dumpit, E. VandenEkart, C. F. Toombs, C. A. Szabo, A monobromobimane-based assay to measure the pharmacokinetic profile of reactive sulphide species in blood. Br. J. Pharmacol. 160, 941-957 (2010).
21. S. Moncada, D. D. Rees, R. Schulz, R. M. Palmer, Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 88, 2166-2170 (1991).
22. G. R. Conahey, G. G. Power, A. O. Hopper, M. H. Terry, L. S. Kirby, A. B. Blood, Effect of inhaled nitric oxide on cerebrospinal fluid and blood nitrite concentrations in newborn lambs. Pediatr. Res. 64, 375-380 (2008).
23. C. Szabó, H. Ischiropoulos, R. Radi, Peroxynitrite: Biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 6, 662-680 (2007).
24. B. S. Zuckerbraun, B. Y. Chin, M. Bilban, J. C. d'Avila, J. Rao, T. R. Billiar, L. E. Otterbein, Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species. FASEB J. 21, 1099-1106 (2007).
25. N. S. Bryan, J. W. Calvert, J. W. Elrod, S. Gundewar, S. Y. Ji, D. J. Lefer, Dietary nitrite supplementation protects against myocardial ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 104, 19144-19149 (2007).
26. J. W. Elrod, J. W. Calvert, J. Morrison, J. E. Doeller, D. W. Kraus, L. Tao, X. Jiao, R. Scalia, L. Kiss, C. Szabo, H. Kimura, C. W. Chow, D. J. Lefer, Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function. Proc. Natl. Acad. Sci. U.S.A. 104, 15560-15565 (2007).
27. A. A. Abba, Exhaled nitric oxide in diagnosis and management of respiratory diseases. Ann. Thorac. Med. 4, 173-181 (2009).
28. M. A. Insko, T. L. Deckwerth, P. Hill, C. F. Toombs, C. Szabo, Detection of exhaled hydrogen sulphide gas in rats exposed to intravenous sodium sulphide. Br. J. Pharmacol. 157, 944-951 (2009).
29. C. F. Toombs, M. A. Insko, E. A. Wintner, T. L. Deckwerth, H. Usansky, K. Jamil, B. Goldstein, M. Cooreman, C. Szabo, Detection of exhaled hydrogen sulphide gas in healthy human volunteers during intravenous administration of sodium sulphide. Br. J. Clin. Pharmacol. 69, 626-636 (2010).
30. D. R. Taylor, M. W. Pijnenburg, A. D. Smith, J. C. De Jongste, Exhaled nitric oxide measurements: Clinical application and interpretation. Thorax 61, 817-827 (2006).
31. I. D. Pavord, D. Shaw, The use of exhaled nitric oxide in the management of asthma. J. Asthma 45, 523-531 (2008).
32. R. Vos, C. Cordemans, B. M. Vanaudenaerde, S. I. De Vleeschauwer, A. Schoonis, D. E. Van Raemdonck, L. J. Dupont, G. M. Verleden, Exhaled carbon monoxide as a noninvasive marker of airway neutrophilia after lung transplantation. Transplantation 87, 1579-1583 (2009).
33. E. B. James, H. J. Vreman, R. J. Wong, D. K. Stevenson, E. Vichinsky, L. Schumacher, J. Y. Hall, J. Simon, D. W. Golden, P. Harmatz, Elevated exhaled carbon monoxide concentration in hemoglobinopathies and its relation to red blood cell transfusion therapy. Pediatr. Hematol. Oncol. 27, 112-121 (2010).
34. J. Zhang, X. Yao, R. Yu, J. Bai, Y. Sun, M. Huang, I. M. Adcock, P. J. Barnes, Exhaled carbon monoxide in asthmatics: A meta-analysis. Respir. Res. 11, 50 (2010).
35. S. Ghosh, J. Gal, N. Marczin, Carbon monoxide: Endogenous mediator, potential diagnostic and therapeutic target. Ann. Med. 42, 1-12 (2010).
36. O. V. Evgenov, P. Pacher, P. M. Schmidt, G. Haskó H. H. Schmidt, J. P. Stasch, NO-independent stimulators and activators of soluble guanylate cyclase: Discovery and therapeutic potential. Nat. Rev. Drug Discov. 5, 755-768 (2006).
37. J. P. Stasch, P. M. Schmidt, P. I. Nedvetsky, T. Y. Nedvetskaya, A. K. H. S. S. Meurer, M. Deile, A. Taye, A. Knorr, H. Lapp, H. Müller, Y. Turgay, C. Rothkegel, A. Tersteegen, B. Kemp-Harper, W. Müller-Esterl, H. H. Schmidt, Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 116, 2552-2561 (2006).
38. F. Martin, P. Baskaran, X. Ma, P. W. Dunten, M. Schaefer, J. P. Stasch, A. Beuve, F. van den Akker, Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J. Biol. Chem. 285, 22651-22657 (2010).
39. H. A. Ghofrani, M. M. Hoeper, M. Halank, F. J. Meyer, G. Staehler, J. Behr, R. Ewert, G. Weimann, F. Grimminger, Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur. Respir. J. 36, 792-799 (2010).
40. H. Lapp, V. Mitrovic, N. Franz, H. Heuer, M. Buerke, J. Wolfertz, W. Mueck, S. Unger, G. Wensing, R. Frey, Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 119, 2781-2788 (2009).
41. R. Motterlini, Carbon monoxide-releasing molecules (CO-RMs): Vasodilatory, anti-ischaemic and anti-inflammatory activities. Biochem. Soc. Trans. 35, 1142-1146 (2007).
42. R. Motterlini, L. E. Otterbein, The therapeutic potential of carbon monoxide. Nat. Rev. Drug Discov. 9, 728-743 (2010).
43. P. Geusens, Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin. Biol. Ther. 9, 649-657 (2009).
44. New Drug Application for Naproxcinod, www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ArthritisDrugsAdvisoryCommittee/UCM211466.pdf.
45. 2S-releasing drugs as pharmaceuticals. J. Med. Chem. 53, 6275-6286 (2010).
46. J. R. Jacobson, Statins in endothelial signaling and activation. Antioxid. Redox Signal. 11, 811-821 (2009).
47. F. N. Salloum, V. Q. Chau, N. N. Hoke, A. Abbate, A. Varma, R. A. Ockaili, S. Toldo, R. C. Kukreja, Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase γ-dependent generation of hydrogen sulfide. Circulation 120 (suppl.), S31-S36 (2009).
48. J. O. Lundberg, E. Weitzberg, M. T. Gladwin, The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat. Rev. Drug Discov. 7, 156-167 (2008).
49. J. W. Calvert, D. J. Lefer, Clinical translation of nitrite therapy for cardiovascular diseases. Nitric Oxide 22, 91-97 (2010).
50. M. Desmard, K. S. Davidge, O. Bouvet, D. Morin, D. Roux, R. Foresti, J. D. Ricard, E. Denamur, R. K. Poole, P. Montravers, R. Motterlini, J. Boczkowski, A carbon monoxide-releasing molecule (CORM-3) exerts bactericidal activity against Pseudomonas aeruginosa and improves survival in an animal model of bacteraemia. FASEB J. 23, 1023-1031 (2009).
51. A. Papapetropoulos, A. Pyriochou, Z. Altaany, G. Yang, A. Marazioti, Z. Zhou, M. G. Jeschke, L. K. Branski, D. N. Herndon, R. Wang, C. Szabó, Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 106, 21972-21977 (2009).
52. M. Bucci, A. Papapetropoulos, V. Vellecco, Z. Zhou, A. Pyriochou, C. Roussos, F. Roviezzo, V. Brancaleone, G. Cirino, Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler. Thromb. Vasc. Biol. 30, 1998-2004 (2010).
53. Funding: The academic research of the author in the field of gaseotransmitters is supported by NIH grant R01GM060915 and a grant from the Shriners Burns Hospitals. Competing interests: The author is a former officer and current shareholder of Ikaria Holdings, a clinical-stage biopharmaceutical company involved in research, development, and clinical therapy in the area of gaseotransmitters.